Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs

Summary

Biogen's anticipated Alzheimer's study has generated both enthusiasm and confusion among scientists, neurologists, investors, and drugmakers regarding tau-targeting drug approaches. The article discusses mixed reactions to the clinical data from key stakeholders in the field.